Friday , November 22 2019
Home / Tag Archives: glenmark

Tag Archives: glenmark

Glenmark Pharma to launch phase 1 trial in solid tumors for GBR 1342

Glenmark Pharmaceuticals is planning to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342. The decision is driven by recent findings derived from a non-interventional human study utilizing a clinically validated CAN script platform. GBR 1342 is based on Glenmark’s proprietary BEAT platform and ... Read More »

Glenmark Pharma launches Nourkrin in Russia

Glenmark Pharmaceuticals has launched of Nourkrin in Russia. Nourkrin is a globally renowned, clinically-proven proteoglycan replacement formula, for addressing one of the key underlying causes of hair loss in males and females. Nourkrin Woman and Nourkrin Man will be exclusively marketed in Russia by Glenmark Impex LLC, the Russian subsidiary ... Read More »

Glenmark Pharmaceuticals executes agreement to transfer its API business

Glenmark Pharmaceuticals has executed business purchase agreement for transfer of the company’s API business to its wholly owned subsidiary — Glenmark Life Sciences on October 9, 2018. The transaction is expected to be completed in the next 2-3 months. Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged ... Read More »

Glenmark Pharmaceutical launches biosimilar of Adalimumab in India

Glenmark Pharmaceuticals has launched the biosimilar of Adalimumab under a licensing agreement with Cadila Healthcare, the Zydus group for the treatment of Plaque Psoriasis and Rheumatoid Arthritis. Developed by the researchers at the Zydus Research Centre, the biosimilar of Adalimumab was first launched by Zydus in 2014 and is manufactured ... Read More »